All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
What are the key updates from ESH: 2nd How I manage: CAR T therapies and bispecific antibodies?
Featured:
Ulrich JägerDuring the European Society of Hematology (ESH) 2nd How I manage: CAR-T therapies and bispecific antibodies for my patients 2023 Congress, the Lymphoma Hub spoke to Ulrich Jӓger, Medical University of Vienna, Vienna, AT. We asked, What are the key updates from ESH 2nd How I manage: CAR-T therapies and bispecific antibodies?
What are the key updates from ESH: 2nd How I manage: CAR T therapies and bispecific antibodies?
Firstly, Jӓger discusses key topics, including the future of chimeric-antigen receptor T-cell therapy and bispecific antibody treatment, the toxicities involved in these treatments, the potential to combine both treatment options, and how to sequence treatments in specific indications. He also highlights key learnings across all indications from the meet-the-expert sessions and debates held at this congress.
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?